Targeting PI3K-gamma in myeloid blood cancers
Lineage-specific signaling and targeting of PI3K gamma in myeloid malignancies
Looking at whether blocking a protein called PI3K-gamma could help adults with myeloid blood cancers such as AML, MDS, and CML.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11254911 on NIH RePORTER |
What this research studies
Researchers at Duke are studying how PI3K-gamma controls growth and survival in myeloid leukemia cells and related disorders. They will use lab-grown cells, animal models, and patient-derived samples to map lineage-specific signaling and test targeted inhibitors. The team aims to identify which myeloid disease types and patient subgroups depend on PI3K-gamma so that therapies can be directed more precisely. Results are intended to guide the development of new drugs or future clinical trials for myeloid malignancies.
Who could benefit from this research
Good fit: Adults with myeloid malignancies such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myelogenous leukemia (CML), or primary myelofibrosis would be the most relevant candidates.
Not a fit: People with lymphoid leukemias, solid tumors, or unrelated medical conditions would likely not directly benefit from this research.
Why it matters
Potential benefit: If successful, this could lead to new targeted treatments for myeloid leukemias that work better and cause fewer side effects than current options.
How similar studies have performed: Lineage-targeted drugs have transformed lymphoid cancers like CLL (for example BTK and PI3Kδ inhibitors), but targeting PI3Kγ in myeloid cancers is relatively new and mainly at the preclinical stage.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Wood, Kris C. — Duke University
- Study coordinator: Wood, Kris C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.